Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study
NCT06603506 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 16
Last updated 2024-11-26
Summary
This study comprises 3 stages:
1. Collection of tumor and blood samples.
2. Creation of organoid models based on tumor samples.
3. Development of functional tests to predict clinical response to treatment.
Conditions
Interventions
- OTHER
-
tumour and blood samples
Tumour and blood samples
Sponsors & Collaborators
-
Centre Francois Baclesse
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-11-21
- Primary Completion
- 2027-10-15
- Completion
- 2027-10-15
Countries
- France
Study Locations
More Related Trials
-
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
NCT02900560 ·Status: TERMINATED ·Phase: PHASE2
-
Prospective Multicenter Study Evaluating Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients With Advanced Refractory Cancers
NCT05267912 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
NCT01420081 ·Status: TERMINATED ·Phase: PHASE2
-
Endometrial Cancer - LOHP Alone and With 5FU
NCT00612495 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients at the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer
NCT06553612 ·Status: RECRUITING ·Phase: NA
-
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT05708924 ·Status: TERMINATED ·Phase: PHASE1
-
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT03586661 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Expression Analysis of the COPB 2 and Bcl-2 in Early Stages of Endometrial Carcinoma
NCT05951426 ·Status: COMPLETED
-
A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT00753480 ·Status: SUSPENDED ·Phase: PHASE1
-
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT06342986 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
NCT05634499 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
NCT01104675 ·Status: COMPLETED ·Phase: PHASE2
-
Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Endometrial Cancer
NCT03567655 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer
NCT05028504 ·Status: RECRUITING ·Phase: PHASE2
-
PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer
NCT01899599 ·Status: COMPLETED ·Phase: PHASE2
-
END-1: First Line Chemotherapy for Advanced or Recurrent Endometrial Carcinoma With Carboplatin and Liposomal Doxorubicin
NCT00401635 ·Status: COMPLETED ·Phase: PHASE2
-
Pembro/Carbo/Taxol in Endometrial Cancer
NCT02549209 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients
NCT05320757 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT02728258 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
NCT05156268 ·Status: COMPLETED ·Phase: PHASE2
-
Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma
NCT05364905 ·Status: COMPLETED
-
Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors
NCT04675320 ·Status: UNKNOWN
-
Letrozole in Patients With Ovarian Tumors
NCT00505661 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT02489006 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
NCT05082025 ·Status: TERMINATED ·Phase: PHASE2